肝癌 － 張文龍臨床腫瘤科專科醫生＠FindDoc.com
FindDoc Facebook : https://www.facebook.com/FindDoc
FindDoc WeChat : 快徳健康香港 FindDoc
FindDoc Instagram：@finddochk
（一）肝癌有什麼治療選擇？ 00:06
（二）標靶藥物是什麼？有什麼好處和副作用？ 00:55
（三）是否每個肝癌患者都適合使用口服標靶藥治療？ 02:36
（四） 標靶藥物費用昂貴有沒有藥物津貼？ 03:13
(本短片作健康教育之用，並不可取代任何醫療診斷或治療。治療成效因人而異，如有疑問，請向專業醫療人士諮詢。)
參考資料：
1. Liu, C. Y., Chen, K. F., & Chen, P. J. (2015). Treatment of Liver Cancer. Cold Spring Harbor perspectives in medicine, 5(9), a021535. https://doi.org/10.1101/cshperspect.a021535
2. M., Kudo; K.-H., Han; S.-L., Ye; J., Zhou; Y.-H., Huang; S.-M., Lin; et al. (2020): Supplementary Material for: A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia- Pacific Primary Liver Cancer Expert Consensus Statements. Karger Publishers. Dataset. https://doi.org/10.6084/m9.figshare.12293318.v1
3. Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., Baron, A., Park, J. W., Han, G.,
Jassem, J., Blanc, J. F., Vogel, A., Komov, D., Evans, T., Lopez, C., Dutcus, C., Guo, M., Saito, K., Kraljevic, S., Tamai, T., … Cheng, A. L. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet (London, England), 391(10126), 1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1
4. Xie, F., Feng, S., Sun, L., & Mao, Y. (2018). The first-line treatment for unresectable hepatocellular carcinoma patients: lenvatinib versus sorafenib, or beyond?. Hepatobiliary surgery and nutrition, 7(3), 221–224. https://doi.org/10.21037/hbsn.2018.06.06
5. OncoLink. (2020). Lenvatinib (Lenvima®). Retrieved from https://www.oncolink.org/cancer- treatment/oncolink-rx/lenvatinib-lenvima-r
資料來源：https://www.FindDoc.com
查詢醫生資訊：
https://www.finddoc.com
figshare 在 FigShare - YouTube 的八卦
Publish all of your data! ... <看更多>